IBS subtypes (IBS-C, IBS-D, IBS-M, IBS-U)
Irritable bowel syndrome (IBS) is a symptom-based diagnosis (abdominal pain related to defecation plus altered stool form or frequency) after alarm features are addressed (Rome IV). Subtypes describe predominant bowel habit over time: IBS-C (constipation), IBS-D (diarrhea), IBS-M (mixed), and IBS-U (unclassified). Subtype guides which dietary and motility trials come first, not which probiotic brand a report highlights.
A stool microbiome panel does not assign IBS-C vs IBS-D. Taxa associated with constipation in research (e.g. methanogens) are hints at population level, not a subtype label on your kit.
For report routing: Reading your microbiome report. For overlapping organic disease: IBD vs functional gut disorders.
What not to conclude
| Situation | Weak conclusion | More accurate framing |
|---|---|---|
| Low diversity on report | IBS-D because “inflammation” | Diversity patterns are non-specific; subtype is symptom-based |
| High methane producer taxa | Confirmed IBS-C | Association in subsets; breath context differs, Methane and colonic gas |
| Low Bifidobacterium | Start high-dose prebiotics | IBS-D may tolerate differently from IBS-C; flare risk real |
| One month of loose stools | Lifelong IBS-D | Subtype uses predominant pattern; acute illness is separate |
| FODMAP trial helped | Everyone with IBS should restrict | Meta-analyses show benefit in IBS overall, not uniform response (Black et al., 2021) |
| Normal calprotectin | Rules out all organic mimic | Bile acid diarrhea, celiac, microscopic colitis still in differential |
Subtype definitions (Rome IV framing)
Classification uses stool form (Bristol Stool Scale) on days with abnormal bowel habit:
| Subtype | Predominant pattern | Typical symptom emphasis |
|---|---|---|
| IBS-C | Hard/lumpy stools (Bristol 1–2) | Straining, incomplete evacuation, bloating |
| IBS-D | Loose/watery stools (Bristol 6–7) | Urgency, cramping, postprandial looseness |
| IBS-M | Both constipation and diarrhea patterns | Alternating or irregular |
| IBS-U | Neither constipation nor diarrhea predominates | Pain-forward |
Subtype can change when bowel habit shifts, retag clinically, not from a single stool kit.
Visceral hypersensitivity and motility abnormalities cut across subtypes; microbiome differences in IBS are statistical at group level, weak for individual diagnosis (Lacy et al., 2021).
Fiber and FODMAP routing by subtype
| Subtype | Often tried first (evidence-aware) | Caution |
|---|---|---|
| IBS-C | Soluble fiber (e.g. psyllium), meta-analyses support symptom benefit in IBS (Moayyedi et al., 2014) | Insoluble wheat bran may worsen gas; titrate |
| IBS-D | Low-FODMAP under dietitian supervision; loperamide for episodic diarrhea per guideline | Aggressive fermentable prebiotics may worsen urgency |
| IBS-M | Pattern-based: reduce triggers during diarrhoeal phases; fiber during constipation phases | One static diet rarely fits |
| IBS-U | Emphasise pain and trigger diary before aggressive restriction | Avoid long unnecessary elimination |
Low-FODMAP is not a microbiome restoration protocol, it reduces fermentable substrate. Reports during strict low-FODMAP reflect that diet, not your habitual community.
Motility and methane context (IBS-C)
Constipation-predominant IBS overlaps with slow transit and, in some patients, elevated methane on breath testing after carbohydrate challenge. Methanogens such as Methanobrevibacter smithii consume hydrogen and associate with slower colonic transit in research, not every IBS-C patient is methane-positive.
ACG constipation guidance prioritises transit vs pelvic floor evaluation before exotic testing (Camilleri et al., 2023). Stool archaea reads are optional research flavour, not a substitute for manometry or balloon expulsion testing when outlet dysfunction is suspected.
Symptom links: Constipation, Bloating.
Inflammation workup, when to escalate beyond IBS framing
Seek clinical reassessment (and do not rely on sequencing inflammation scores) if:
- Blood in stool, nocturnal symptoms, unintentional weight loss, Red flags
- Elevated calprotectin or CRP
- Family history of IBD or colorectal cancer
- Diarrhea-predominant with greasy stools or nocturnal diarrhea (bile acid or malabsorption workup)
- Persistent symptoms despite reasonable IBS trials
IBD vs functional gut disorders · Gut inflammation markers.
Probiotics and microbiome reports in IBS
Meta-analyses show modest overall benefit for selected multi-strain probiotics in IBS (Ford et al., 2019), effect sizes are symptom scores, not taxon restoration guarantees. Strain and subtype matter; report lines listing low Bifidobacterium do not prescribe a specific product. See Probiotics and prebiotics.